- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06242418
ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) (REVISE)
Value of ctDNA in Surveillance of Chemosensitivity and Regimen Adjustment in Stage III Colon Cancer: a Phase II Randomized Controlled Trial (REVISE Trial)
Colon cancer is one of the most common malignant tumors with an increasing incidence rate in China. Surgical resection is still the main treatment for colon cancer at present. Radical surgery followed by three/six months chemotherapy is the standard of care for stage III colon cancer; however, patients with different risk factors have different prognosis. The IDEA trial divided stage III colon cancer patients into low-risk (T1-3/N1) and high-risk (T4 or N2) groups, and showed that for some low-risk patients, three months chemotherapy did not decrease survival outcomes, while for some high-risk patients, the recurrence risk was still high even after six months chemotherapy. Therefore, it's worth to explore other risk stratification factors beyond T and N stage for these patients.
Circulating tumor DNA (ctDNA) is derived from cancer cells and can be detected in blood. Literatures have reported that ctDNA can be used for tumor diagnosis, therapeutic monitoring, and prognosis assessment in multiple cancers, including colon cancer. The GERCOR-PRODIGE trial, an accompanying study of IDEA, reported that in the high-risk group of stage III colon cancer, patients with ctDNA-positive and receiving six months chemotherapy had similar prognosis to these with ctDNA-negative and receiving three months chemotherapy; in the low-risk group, patients with ctDNA-negative and receiving three or six months chemotherapy had similar prognosis to patients with ctDNA-positive and receiving 6 months chemotherapy, but patients with ctDNA-positive and receiving three months chemotherapy had the worst prognosis. The results of this trial suggests that ctDNA can be potentially used as a further stratification factor to guide adjuvant chemotherapy for stage III colon cancer.
Several RCTs have shown that double-drug regimens chemotherapy based on oxaliplatin (FOLFOX and XELOX) can improve the prognosis of patients with stage III colon cancer. Therefore, the ESMO, NCCN, and CSCO guidelines recommend FOLFOX or XELOX for stage III colon cancer. The 2-year disease-free survival rate of these patients who received FOLFOX or XELOX chemotherapy was about 80%. It is worth to further explore how to improve the prognosis of these patients. Recently, the triple-drug regimens of oxaliplatin, irinotecan, and fluoropyrimidine (FOLFOXIRI) has been found to be superior to FOLFOX or XELOX for metastatic colorectal cancer in terms of response rate and survival. Currently, research on FOLFOXIRI plus targeted therapy in metastatic colorectal cancer is progressing rapidly, but there is little research on the use of FOLFOXIRI as adjuvant chemotherapy for stage III colon cancer. There is an ongoing international multicenter phase III RCT comparing FOLFOXIRI and FOLFOX6 adjuvant chemotherapy for high-risk stage III colon cancer patients, but it did not further stratify patients based on postoperative ctDNA status, which may result in some patients receiving excessive chemotherapy.
The present study plans to enroll patients with stage III colon cancer with positive ctDNA within 1 month after surgery. These patients will receive 2 cycles of XELOX chemotherapy followed by retesting ctDNA. During the waiting period of the ctDNA results (approximately 3 weeks due to the testing time), all patients will receive another cycle of XELOX chemotherapy. If the ctDNA remains positive, the patients will be randomly assigned to receive 8 cycles of FOLFOXIRI as intensified adjuvant chemotherapy or 5 cycles of XELOX regimen as standard adjuvant chemotherapy. If the ctDNA is negative, the patients will continue to receive 5 cycles of XELOX chemotherapy. Within 3 weeks after the completion or termination of chemotherapy, ctDNA will be retested again. The aims of this study are to explore the value of ctDNA in surveillance of chemosensitivity and to preliminarily evaluate whether the intensified chemotherapy with FOLFOXIRI can increase ctDNA clearance as well as its safety in stage III colon cancer.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ziqiang Wang
- Phone Number: +8685422480
- Email: wangziqiang@scu.edu.cn
Study Contact Backup
- Name: Qingbin Wu
- Phone Number: +8685422480
- Email: wuqingbin214@scu.edu.cn
Study Locations
-
-
Guizhou
-
Guiyang, Guizhou, China
- Recruiting
- The Affiliated Hospital Of Guizhou Medical University
-
Contact:
- Zhen Yunhuan
-
-
Sichuan
-
Chengde, Sichuan, China, 610041
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Ziqiang Wang
-
Chengdu, Sichuan, China
- Recruiting
- Sichuan Cancer Hospital
-
Contact:
- Liu Chao
-
Chengdu, Sichuan, China
- Recruiting
- The Third People's Hospital of Chengdu
-
Contact:
- Zhang Yuanchuan
-
Contact:
- Wang Meng
-
Chengdu, Sichuan, China
- Recruiting
- People's Hospital of Sichuan Province
-
Contact:
- Pang Minghui
-
Chengdu, Sichuan, China
- Recruiting
- Shang Jin Hospital of West China Hospital, Sichuan University
-
Contact:
- Wei Mingtian
-
Chengdu, Sichuan, China
- Recruiting
- West China Tianfu Hospital, Sichuan University
-
Contact:
- Deng Xiangbing
-
-
Yunnan
-
Kunming, Yunnan, China
- Recruiting
- Yunnan Cancer Hospital
-
Contact:
- Li Yunfeng
-
Contact:
- Liu Ping
-
Kunming, Yunnan, China
- Recruiting
- First Affiliated Hospital of Kunming Medical University
-
Contact:
- Zeng Yujian
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Age 18-75 years, regardless of gender.
Tumor located in the colon (the distance from the lower margin of the tumor to the anus is greater than 12 cm).
Radical surgery performed, and the postoperative pathological staging is stage III, i.e., T1-4N1-2M0 (AJCC TNM staging, 8th edition, 2017).
No local or distant tumor recurrence was found in imaging examination. ⑤ ECOG performance status: 0-1. ⑥ No history of allergy to fluoropyrimidines or platinum-based drugs.
- Voluntarily participating in this study, signing an informed consent form, good compliance, and cooperation with follow-up.
Exclusion Criteria:
History of other malignant tumors within the past five years (excluding basal cell carcinoma and/or cervical carcinoma in situ after radical surgery).
Previous chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc., for colon cancer.
Patients suspected or confirmed to have lynch syndrome. ④ Severe cardiovascular or cerebrovascular diseases, liver or kidney dysfunction, severe primary hematological diseases, etc.
Allergy to fluoropyrimidines or platinum-based drugs.
⑥ Any unstable condition or situation that may harm patient safety or compliance with the study, such as fertility needs, pregnancy, breastfeeding, depression, bipolar disorder, obsessive-compulsive disorder, or schizophrenia.
⑦ Patients deemed unsuitable for participation in this study by the investigator.
⑧ Recently participated in or currently participating in other clinical trials of drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FOLFOXIRI
Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
|
Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
|
Active Comparator: XELOX
Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
|
Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in value of ctDNA concentration
Time Frame: six months
|
Defined as the change in value of ctDNA measured after 2 cycles of XELOX (ctDNA2) and after the completion or termination of chemotherapy (ctDNA3).
△ctDNA= ctDNA3 - ctDNA2.
|
six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ctDNA clearance rate
Time Frame: six months
|
Defined as the proportion of patients whose ctDNA becomes negative after the completion or termination of chemotherapy to the total patient.
|
six months
|
disease-free survival
Time Frame: two years
|
The time from randomization to local recurrence, distant metastasis, or death.
|
two years
|
metastasis-free survival
Time Frame: two years
|
The time from randomization to distant metastasis.
|
two years
|
Number of participants with treatment-related adverse events as assessed by CTCAE 5.0.
Time Frame: two years
|
Number of participants with treatment-related adverse events as assessed by CTCAE 5.0.
|
two years
|
quality of life as assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
Time Frame: two years
|
The EORTC QLQ-C30 consists of 30 items, including 5 functional scales (physical function, role function, cognitive function, emotional function, social function), 3 symptom scales (fatigue, pain, nausea and vomiting), 6 individual measurement items (dysphagia, loss of appetite, sleep disorders, constipation, diarrhea, economic difficulties), and 1 patient self-assessment item (overall health status).
Each of the first 28 items score 1 to 4. The higher the score, the worse the quality of life.
The last 2 items score 1 to 7. The higher the score, the best the quality of life.
|
two years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023#1998
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer
-
National Cancer Institute (NCI)NSABP Foundation IncCompletedColon Adenocarcinoma | Stage IIIA Colon Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage IIIC Colon Cancer AJCC v7 | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineRecruitingStage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon CancerItaly
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedFatigue | Depressive Symptoms | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Psychosocial Effects of Cancer and Its Treatment | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingStage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8United States
-
Hospital da Senhora da OliveiraCompletedColon Cancer | Colon Adenoma | Colon Polyp | Colon Rectal CancerPortugal
-
National Cancer Institute (NCI)CompletedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
Howard S. Hochster, MDRecruitingStage IV Colon Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVC Colon Cancer AJCC v8 | Metastatic Colon CarcinomaUnited States
-
NorgineXolomon Tree S.L.CompletedColon Cancer | Colon Disease | Colon CleansingSpain, Portugal
Clinical Trials on FOLFOXIRI
-
Azienda Ospedaliero, Universitaria PisanaCompletedPancreatic Carcinoma Stage IIIItaly
-
Fujian Cancer HospitalNot yet recruitingAdvanced Colorectal Cancer
-
AIPING ZHOUCompletedLocally Advanced Rectal CancerChina
-
Catharina Ziekenhuis EindhovenNot yet recruiting
-
Kasr El Aini HospitalCompletedMetastatic Colorectal CancerEgypt
-
Gruppo Oncologico del Nord-OvestCompletedMetastatic Colo-rectal CancerItaly
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingRectal Cancer | Chemotherapy Effect
-
Fudan UniversityRecruitingColorectal Cancer | Vitamin C | GLUT3China
-
Gruppo Oncologico del Nord-OvestCompletedMetastatic Colorectal CancerItaly
-
Sun Yat-sen UniversityNot yet recruiting